Kristi Arceneaux
Primary Care · Houston, TXNPI 1104395417
Payments from drug & device makers
Across 14 payments — averaging $24.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$105
- Convatec Inc.$50
- Coloplast$47
- Urovant Sciences Inc$42
- Astellas Pharma US Inc$38
- 180 Medical, Inc.$28
- plus $35 from 2 others
What the payments were for
- Food & beverage$347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 4 | $105 |
| Convatec Inc. | 2 | $50 |
| Coloplast | 2 | $47 |
| Urovant Sciences Inc | 2 | $42 |
| Astellas Pharma US Inc | 1 | $38 |
| 180 Medical, Inc. | 1 | $28 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $12 |
How this compares
$347 in reported general payments places this provider in the 50th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 169 | $109,593 |
| GemtesaVibegron | 81 | $54,322 |
| Mirabegron ErMirabegron | 24 | $18,536 |
| Methenamine Hippurate | 81 | $4,941 |
| Estradiol | 84 | $4,822 |
| Trospium Chloride | 86 | $4,621 |
| PremarinEstrogens, Conjugated | 11 | $4,577 |
| Tamsulosin Hcl | 347 | $3,918 |
| Solifenacin Succinate | 115 | $3,021 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,156 |
| Testosterone | 17 | $1,028 |
| Fosfomycin Tromethamine | 14 | $861 |
| Oxybutynin Chloride ErOxybutynin Chloride | 42 | $736 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 52 | $725 |
| Finasteride | 59 | $631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $38 | $109,593169 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $105 | $54,32281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 563 primary care providers in Texas.
Other primary care in Houston
- Mary GibbensHouston$42K
- Joanna LarsonHouston$7K
- Mei ChenHouston$4K
- Catherine PenceHouston$3K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Roxana RoposGrapevine$13K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.